10 May 2024
10 May 2024
The randomised, double-blind study involved 1,095 patients to assess adjuvant treatment with Keytruda plus chemotherapy.
The transformative potential of decentralised clinical trials (DCTs) has been heralded in recent years.
The Phase III trial of anito-cel for multiple myeloma is anticipated to begin in late 2024.
Marking yet another chapter in approval pathway for Multikine, CEL-SCI has announced a confirmatory study with new inclusion criteria.
Key secondary endpoints also showed mazdutide's superior benefits in both glucose-lowering and weight loss.
The Phase II segment of the AlphaBreak trial is anticipated to conclude enrolment of around 60 patients by the end of this year.
Assessing the efficacy of Namodenoson versus placebo in 140 MASH patients is the trial’s primary efficacy objective.
Marinus expects to share data from the Phase III RAISE trial of IV ganaxolone for the treatment of status epilepticus later in the summer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
